PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma

被引:2
作者
Lo, Andrea C. [1 ]
James, Lyndon P. [2 ,3 ]
Prica, Anca [4 ]
Raymakers, Adam [5 ]
Peacock, Stuart [5 ]
Qu, Melody [6 ]
Louie, Alex, V [7 ]
Savage, Kerry J. [8 ]
Sehn, Laurie H. [8 ]
Hodgson, David [9 ]
Yang, Joanna C. [10 ]
Eich, Hans T. T. [11 ]
Wirth, Andrew [12 ]
Hunink, M. G. Myriam [3 ,13 ]
机构
[1] Univ British Columbia, Dept Radiat Oncol, BC Canc, Vancouver, BC, Canada
[2] Harvard Univ, PhD Program Hlth Policy, Cambridge, MA 02138 USA
[3] Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA USA
[4] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
[5] BC Canc, Canc Control Res, Vancouver, BC, Canada
[6] Western Univ, London Hlth Sci Ctr, Dept Radiat Oncol, London, ON, Canada
[7] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON, Canada
[8] BC Canc, Dept Med Oncol, Ctr Lymphoid Canc, Vancouver, BC, Canada
[9] Princess Margaret Canc Ctr, Radiat Med Program, Toronto, ON, Canada
[10] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[11] Univ Hosp Muenster, Dept Radiat Oncol, Munster, Germany
[12] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[13] Erasmus Univ, Clin Epidemiol & Radiol, Rotterdam, Netherlands
关键词
undergo Key Words; PET; CT; follicular lymphoma; radiation therapy; cost-effectiveness analysis; staging; POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; RITUXIMAB MAINTENANCE; 1ST-LINE TREATMENT; INDOLENT LYMPHOMA; F-18-FDG PET/CT; WAIT APPROACH; OPEN-LABEL; FDG-PET;
D O I
10.2967/jnumed.121.262324
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The objective was to assess the cost-effectiveness of staging PET/CT in early-stage follicular lymphoma (FL) from the Canadian health-care system perspective. Methods: The study population was FL patients staged as early-stage using conventional CT imaging and planned for curative-intent radiation therapy (RT). A decision analytic model simulated the management after adding staging PET/CT versus using staging CT alone. In the no-PET/CT strategy, all patients proceeded to curative-intent RT as planned. In the PET/CT strategy, PET/CT information could result in an increased RT volume, switching to a noncurative approach, or no change in RT treatment as planned. The subsequent disease course was described using a state-transition cohort model over a 30-y time horizon. Diagnostic characteristics, probabilities, utilities, and costs were derived from the literature. Baseline analysis was performed using quality-adjusted life years (QALYs), costs (2019 Canadian dollars), and the incremental cost-effectiveness ratio. Deterministic sensitivity analyses were conducted, evaluating net monetary benefit at a willingness-to-pay threshold of $100,000/ QALY. Probabilistic sensitivity analysis using 10,000 simulations was performed. Costs and QALYs were discounted at a rate of 1.5%. Results: In the reference case scenario, staging PET/CT was the dominant strategy, resulting in an average lifetime cost saving of $3,165 and a gain of 0.32 QALYs. In deterministic sensitivity analyses, the PET/CT strategy remained the preferred strategy for all scenarios supported by available data. In probabilistic sensitivity analysis, the PET/CT strategy was strongly dominant in 77% of simulations (i.e., reduced cost and increased QALYs) and was cost-effective in 89% of simulations (i.e., either saved costs or had an incremental costeffectiveness ratio below $100,000/QALY). Conclusion: Our analysis showed that the use of PET/CT to stage early-stage FL patients reduces cost and improves QALYs. Patients with early-stage FL should undergo PET/CT before curative-intent RT.
引用
收藏
页码:543 / 548
页数:6
相关论文
共 60 条
  • [1] Systematic Review on the Additional Value of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging Follicular Lymphoma
    Adams, Hugo J. A.
    Nievelstein, Rutger A. J.
    Kwee, Thomas C.
    [J]. JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2017, 41 (01) : 98 - 103
  • [2] Incidence and Economic Impact of Incidental Findings on 18F-FDG PET/CT Imaging
    Adams, Scott J.
    Rakheja, Rajan
    Bryce, Rhonda
    Babyn, Paul S.
    [J]. CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES, 2018, 69 (01): : 63 - 70
  • [3] [Anonymous], Data tables in PDF and TXT format
  • [4] [Anonymous], 2013, Schedule of Benefits for Physician Services under the Health Insurance Act
  • [5] [Anonymous], Schedule of benefits for laboratory services
  • [6] [Anonymous], 2021, Non-Hodgkin's lymphoma
  • [7] [Anonymous], 2017, Guidelines for the Economic Evaluation of Health Technologies: Canada, V4th, P1
  • [8] [Anonymous], Treanda for non-Hodgkin lymphoma
  • [9] [Anonymous], 2012, OPEN PHARMACOECON HL
  • [10] Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
    Ardeshna, Kirit M.
    Qian, Wendi
    Smith, Paul
    Braganca, Nivette
    Lowry, Lisa
    Patrick, Pip
    Warden, June
    Stevens, Lindsey
    Pocock, Christopher F. E.
    Miall, Fiona
    Cunningham, David
    Davies, John
    Jack, Andrew
    Stephens, Richard
    Walewski, Jan
    Ferhanoglu, Burhan
    Bradstock, Ken
    Linch, David C.
    [J]. LANCET ONCOLOGY, 2014, 15 (04) : 424 - 435